ArticlePCN reports : psychiatry and clinical neurosciences2025
Electroconvulsive therapy for depression and oral dyskinesia in a patient who developed parkinsonism induced by valbenazine.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report.Neuropsychopharmacology reports · 2026Article
- Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Electroconvulsive therapy for depression and oral dyskinesia in a patient who developed parkinsonism induced by valbenazine.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tardive dyskinesia (TD) is a movement disorder related to long-term antipsychotic use and characterized by involuntary repetitive movements that often affect the oral and facial muscles. Although valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is an effective treatment of TD, it may induce drug-induced parkinsonism (DIP) in some patients. Electroconvulsive therapy (ECT) improves depressive symptoms and certain movement disorders; however, its role in managing TD, particularly in patients intolerant to VMAT2 inhibitors because of DIP, remains elusive. Case Presentation: Herein, we describe a 65-year-old Japanese woman with a history of major depressive episodes and oral dyskinesia. The patient was treated with valbenazine for oral dyskinesia; however, she developed DIP, requiring valbenazine discontinuation. After the worsening of depression, the patient was hospitalized and underwent 10 sessions of modified ECT, which remarkably helped improving depressive symptoms and oral dyskinesia. Conclusion: This case suggests that ECT could be a viable treatment option for managing patients with depression and oral dyskinesia who are susceptible of valbenazine-induced parkinsonism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.